Stay updated with breaking news from 37555810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Private Wealth Partners LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,064 shares of the biopharmaceutical company’s stock after purchasing an additional 1,815 shares during the period. Private Wealth Partners […]
PFG Investments LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 16,118 shares of the biopharmaceutical company’s stock after selling 804 shares during the period. PFG Investments LLC’s holdings in Gilead Sciences were worth […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) and Ambrx Biopharma (NYSE:AMAM – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Earnings and Valuation This table compares Gilead Sciences […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective increased by Barclays from $82.00 to $85.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on GILD. Leerink Partnrs […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target hoisted by Barclays from $82.00 to $85.00 in a research report report published on Tuesday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on GILD. Deutsche Bank Aktiengesellschaft began […]